BERLIN--(BUSINESS WIRE)--ResMed today announced it has launched the SERVE-HF study at the 18th European Respiratory Society’s (ERS) annual congress in Berlin, Germany. The study is to investigate the use of its AutoSet CS™2 device in the treatment of sleep-disordered breathing that affects patients with chronic heart failure.
